Blood Lead Levels in Patients with Age-Related Macular Degeneration: A Case-Control Study

Document Type : Original Article(s)

Authors

1 Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Ophthalmology, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Department of Medicinal Chemistry, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Background: This study aimed to evaluate blood lead levels in patients with age-related macular degeneration (AMD).
Methods: This case-control study was conducted on patients with AMD and healthy controls at Ahvaz, Khozestan, Iran. The control group was randomly selected from the general outpatient clinic. Two groups were matched for the following parameters: age, sex, smoking, lipid profiles, past vascular diseases, and history of ophthalmic surgery.
Findings: Ninety-five AMD patients (55.8% male, mean age 69.93 ± 10.17 years) and 95 controls (31.6% male, mean age 65.50 ± 7.65 years) were enrolled. The mean blood lead level in the case and control groups was
 25.70 ± 10.08 and 24.25 ± 9.74 µg/dL, respectively (P = 0.46). Also, after adjusting for confounding factors, there was no significant difference between the two groups' blood lead levels (P = 0.4).
Conclusion: No significant differences were found in the blood lead levels, indicative of short-term exposure, between patients with AMD and the control group.

Highlights

Mostafa Feghhi: Google Scholar, PubMed

Mohammad Malekahmadi: Google Scholar, PubMed

Fereydoun Farahi: PubMed

Zahra Ramezani: Google Scholar, PubMed

Ali Shahsavari: Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108(4): 697-704.
  2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291(15): 1900-1.
  3. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010; 10: 31.
  4. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358(24): 2606-17.
  5. Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology 2004; 111(3): 513-7.
  6. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119(3): 571-80.
  7. Hashemi H, Ghafari E, Khabazkhoob M, Noori J, Taheri A, Eshghabadi A, et al. Age-related macular degeneration in an Iranian population. Iranian Journal of Ophthalmology 2015; 26(4): 203-11.
  8. Shaw PX, Stiles T, Douglas C, Ho D, Fan W, Du H, et al. Oxidative stress, innate immunity, and age-related macular degeneration. AIMS Mol Sci 2016; 3(2): 196-221.
  9. Chakravarthy U, Augood C, Bentham G, de Jong P, Rahu M, Seland J, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 2007; 114(6): 1157-63.
  10. Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 2007; 335(7623): 755.
  11. Fletcher AE, Bentham GC, Agnew M, Young IS, Augood C, Chakravarthy U, et al. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol 2008; 126(10): 1396-403.
  12. Thakkinstian A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K, et al. Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 2006; 15(18): 2784-90.
  13. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6½ years in the Rotterdam Study. Archives of ophthalmology 2003; 121(4): 519-26.
  14. Wu EW, Schaumberg DA, Park SK. Environmental cadmium and lead exposures and age-related macular degeneration in US adults: the National Health and Nutrition Examination Survey 2005 to 2008. Environ Res 2014; 133: 178-84.
  15. Heesterbeek TJ, Rouhi-Parkouhi M, Church SJ, Lechanteur YT, Lorés-Motta L, Kouvatsos N, et al. Association of plasma trace element levels with neovascular age-related macular degeneration. Exp Eye Res 2020; 201: 108324.
  16. Bede-Ojimadu O, Orish CN, Bocca B, Ruggieri F, Frazzoli C, Orisakwe OE. Trace elements exposure and risk in age-related eye diseases: a systematic review of epidemiological evidence. J Environ Sci Health C Toxicol Carcinog 2021; 39(3): 293-339.
  17. Kim H-C, Jang T-W, Chae H-J, Choi W-J, Ha M-N, Ye B-J, et al. Evaluation and management of lead exposure. Ann Occup Environ Med 2015; 27: 30.
  18. Gurer H, Ercal N. Can antioxidants be beneficial in the treatment of lead poisoning? Free Radic Biol Med 2000; 29(10): 927-45.
  19. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease—a systematic review. Environmental health perspectives 2007; 115(3): 472-82.
  20. Mecocci P, Mariani E, Cornacchiola V, Polidori M. Antioxidants for the treatment of mild cognitive impairment. Neurol Res 2004; 26(5): 598-602.
  21. Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003; 126(Pt 1): 5-19.
  22. Jacob B, Ritz B, Heinrich J, Hoelscher B, Wichmann H-E. The effect of low-level blood lead on hematologic parameters in children. Environ Res 2000; 82(2): 150-9.
  23. Park SJ, Lee JH, Woo SJ, Kang SW, Park KH, Epidemiologic Survey Committee of Korean Ophthalmologic Society. Five heavy metallic elements and age-related macular degeneration: Korean National Health and Nutrition Examination Survey, 2008–2011. Ophthalmology 2015; 122(1): 129-37.
  24. Yuki K, Dogru M, Imamura Y, Kimura I, Ohtake Y, Tsubota K. Lead accumulation as possible risk factor for primary open-angle glaucoma. Biol Trace Elem Res 2009; 132(1-3): 1-8.
  25. Wills N, Ramanujam VS, Chang J, Kalariya N, Lewis J, Weng T-X, et al. Cadmium accumulation in the human retina: effects of age, gender, and cellular toxicity. Experimental eye research 2008; 86(1): 41-51.
  26. Erie JC, Butz JA, Good JA, Erie EA, Burritt MF, Cameron JD. Heavy metal concentrations in human eyes. Am J Ophthalmol 2005; 139(5): 888-93.
  27. Erie JC, Good JA, Butz JA. Excess lead in the neural retina in age-related macular degeneration. Am J Ophthalmol 2009; 148(6): 890-4.
  28. Shen X-F, Huang P, Fox DA, Lin Y, Zhao Z-H, Wang W, et al. Adult lead exposure increases blood-retinal permeability: A risk factor for retinal vascular disease. Neurotoxicology 2016; 57: 145-52.
  29. Calabrese A, Bernard J-B, Hoffart L, Faure G, Barouch F, Conrath J, et al. Wet versus dry age-related macular degeneration in patients with central field loss: different effects on maximum reading speed. Invest Ophthalmol Vis Sci 2011; 52(5): 2417-24.
  30. Hwang HS, Lee SB, Jee D. Association between blood lead levels and age-related macular degeneration. PLoS One 2015; 10(8): e0134338.
  31. Güngör ED, Yülek F, Serkant U, Toklu Y, Hocaoğlu A, Şimsek Ş. Blood lead and cadmium in age related macular degeneration in a Turkish urban population. J Trace Elem Med Biol 2018; 48: 16-9.
  32. Hsu P-C, Guo YL. Antioxidant nutrients and lead toxicity. Toxicology. 2002;180(1):33-44.
  33. Beatty S, Koh H-H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45(2): 115-34.
  34. Becker K, Kaus S, Krause C, Lepom P, Schulz C, Seiwert M, et al. German Environmental Survey 1998 (GerES III): environmental pollutants in blood of the German population. Int J Hyg Environ Health 2002; 205(4): 297-308.
  35. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. Exposure of the US population to lead, 1991-1994. Environ Health Perspect 1998; 106(11): 745-50.
  36. Rhee SY, Hwang Y-C, Woo J-t, Sinn DH, Chin SO, Chon S, et al. Blood lead is significantly associated with metabolic syndrome in Korean adults: an analysis based on the Korea National Health and Nutrition Examination Survey (KNHANES), 2008. Cardiovasc Diabetol 2013; 12: 9.
  37. Lee B-K, Kim Y. Association between bone mineral density and blood lead level in menopausal women: Analysis of 2008–2009 Korean national health and nutrition examination survey data. Environ Res 2012;115:59-65.
  38. Sim C-S, Kim Y, Lee H, Park C-Y, Ham J-O, Lee B-K. Iron deficiency increases blood lead levels in boys and pre-menarche girls surveyed in KNHANES 2010–2011. Environ Res 2014; 130: 1-6.
  39. Won YS, Kim JH, Kim YS, Bae KH. Association of internal exposure of cadmium and lead with periodontal disease: a study of the Fourth Korean National Health and Nutrition Examination Survey. J Clin Periodontol 2013; 40(2): 118-24.
  40. Kim Y, Lee B-K. Associations of blood lead, cadmium, and mercury with estimated glomerular filtration rate in the Korean general population: analysis of 2008–2010 Korean National Health and Nutrition Examination Survey data. Environ Res 2012; 118: 124-9.
  41. Wills N, Kalariya N, Ramanujam VS, Lewis J, Abdollahi SH, Husain A, et al. Human retinal cadmium accumulation as a factor in the etiology of age-related macular degeneration. Exp Eye Res 2009; 89(1): 79-87.
  42. Adonaylo V, Oteiza PI. Pb2+ promotes lipid oxidation and alterations in membrane physical properties. Toxicology 1999; 132(1): 19-32.
  43. Fox DA, Srivastava D, Hurwitz RL. Lead-induced alterations in rod-mediated visual functions and cGMP metabolism: new insights. Neurotoxicology 1994; 15(3): 503-12.
  44. Hsu JM. Lead toxicity as related to glutathione metabolism. J Nutr 1981; 111(1): 26-33.
  45. Ito Y, Niiya Y, Kurita H, Shima S, Sarai S. Serum lipid peroxide level and blood superoxide dismutase activity in workers with occupational exposure to lead. Int Arch Occup Environ Health 1985; 56(2): 119-27.
  46. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283(5407): 1482-8.
  47. Sundelin S, Wihlmark U, Nilsson SEG, Brunk UT. Lipofuscin accumulation in cultured retinal pigment epithelial cells reduces their phagocytic capacity. Curr Eye Res 1998; 17(8): 851-7.
  48. Boulton M, Dontsov A, Jarvis-Evans J, Ostrovsky M, Svistunenko D. Lipofuscin is a photoinducible free radical generator. J Photochem Photobiol B 1993; 19(3): 201-4.
  49. Holz FG, Schütt F, Kopitz J, Eldred GE, Kruse FE, Völcker H, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 1999; 40(3): 737-43.
  50. Jünemann AG, Stopa P, Michalke B, Chaudhri A, Reulbach U, Huchzermeyer C, et al. Levels of aqueous humor trace elements in patients with non-exsudative age-related macular degeneration: a case-control study. PloS One 2013; 8(2): e56734.
Journal of Isfahan Medical School
Volume 42, Issue 786
2nd Week, December
November and December 2024
Pages 876-883

Files

History

  • Receive Date: 27 August 2024
  • Revise Date: 16 October 2024
  • Accept Date: 28 October 2024

Share

How to cite

Statistics